---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-23-000012"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T05:22:43.006930+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Maravai Q4 revenue $204.7M, adj EPS $0.35; 2023 guidance $420-460M; acquires Alphazyme

## Summary
- Q4 revenue $204.7M (-10% YoY); net income $87.4M; adjusted diluted EPS $0.35.
- Full year 2022 revenue $883.0M (+10% YoY); net income $490.7M; adjusted EPS $1.80.
- Base business revenue (ex-COVID CleanCap) up 67% in Q4 and 17% full year.
- 2023 revenue guidance $420M-$460M; base business growth expected >20%.
- Acquired Alphazyme, LLC (private enzyme manufacturer); announced CEO succession plan.

## SEC filing metadata
- accession: 0001823239-23-000012
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/mrvi-20230222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-23-000012
- JSON: https://secwatch.observer/filing/0001823239-23-000012.json
- Plain text: https://secwatch.observer/filing/0001823239-23-000012.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported fourth quarter ended December 31, 2022 results: revenue $204.7 million, net income $87.4 million, EPS $0.35.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: $204.7 million
  - Net income: $87.4 million
  - EPS: $0.35
  - Result: reported results
  source text: Quarterly revenue of $204.7 million, Net income of $87.4 million, and Adjusted fully diluted earnings per share (EPS) of $0.35
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported full year ended December 31, 2022 results: revenue $883.0 million, net income $490.7 million, EPS $1.80.
  - Period: full year ended December 31, 2022
  - Revenue: $883.0 million
  - Net income: $490.7 million
  - EPS: $1.80
  - Result: reported results
  source text: Annual revenue of $883.0 million, Net income of $490.7 million and Adjusted fully diluted EPS of $1.80
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported full year 2023 results: revenue $420.0 million to $460.0 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $420.0 million to $460.0 million
  - Guidance: initiated
  - Result: guidance update
  source text: Introduced 2023 revenue guidance range of $420.0 million to $460.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.